Clinical trial
An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
NCT02783482 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
- Lead sponsor
- Green Cross Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- July 31, 2019
- Enrollment
- 49 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.